Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study

Final Phase I results for the BiTE construct blinatumomab in relapsed/refractory non-Hodgkin lymphoma.

Publication · 2024-11-06

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

All white papers, case studies, publications and blogs.

Peer-reviewed and journal articles.

Talk to a senior contact about the work behind this.